Posts by: Daniela Semedo, PhD

Daniela Semedo, PhD

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

March 23, 2017March 23, 2017

Novartis’ Cosentyx Eliminates Psoriasis for Up to Two Years, Clinical Trial Shows

News

Novartis’ Cosentyx (secukinumab) may modify the course of moderate-to-severe psoriasis so that a patient achieves long-term, treatment-free clear skin, according to extension trial results. The trial (A2302E1) was an extension ... Read more

March 16, 2017March 16, 2017

MetrioPharm Reports Positive Phase 2a Trial Results of MP1032 for Plaque Psoriasis

News

MetrioPharm reported positive results from a Phase 2a clinical trial evaluating its drug candidate MP1032 in patients with moderate to severe plaque psoriasis, and now plans to conduct a Phase ... Read more

March 9, 2017

Cosentyx Effective For Re-Treating Plaque Psoriasis Patients, Novartis Analysis Shows

News

Swiss drugmaker Novartis says re-treatment with Cosentyx (secukinumab) for moderate to severe plaque psoriasis helps patients rapidly regain clear or almost clear skin (Psoriasis Area Severity Index, PASI 100 or 90) following relapse during a treatment ... Read more

March 7, 2017

Otezla Found Superior to Placebo in Treating Moderate Plaque Psoriasis, Celgene Reports

News

Celgene reported positive results from its Phase 4 UNVEIL clinical trial that evaluated Otezla (apremilast) in patients with moderate plaque psoriasis with a body surface area (BSA) of 5-10%. The results were ... Read more

February 21, 2017

Biologic Agents May Up Risk of Squamous Cell Carcinoma Among Psoriasis Patients, Study Suggests

News

An increased incidence of cutaneous squamous cell carcinoma was found among psoriasis patients who were treated with biologic agents. A study with those results, “Malignancy rates in a large cohort ... Read more

February 9, 2017

Stelara Remains Effective Psoriasis Treatment Long After Others Fizzle, Study Shows

News

Janssen Biotech’s Stelara (ustekinumab) remains an effective treatment for severe psoriasis long after other therapies have lost their punch, a study shows. The research, “Biologic drug survival in Israeli psoriasis patients,” ... Read more

January 26, 2017

FDA Approves Generic Version of Topicort Spray for Plaque Psoriasis

News

The U.S. Food and Drug Administration (FDA) has approved Perrigo’s generic version of Topicort (desoximetasone topical spray, 0.25%) to treat plaque psoriasis, the company announced. Topicort, owned by Taro Pharmaceuticals US, is a ... Read more

January 24, 2017

Cosentyx Is Better, Cheaper Therapy Than Humira for US Psoriatic-arthritis Patients

News

Cosentyx (secukinumab, Novartis) is a better and cheaper treatment for psoriatic arthritis in the United States than Humira (adalimumab, AbbVie), a study has concluded. The research, “Comparison of Secukinumab Vs ... Read more

January 19, 2017January 19, 2017

Coherus Reports Positive 24-Week Trial Results for Humira Biosimilar in Psoriasis Patients

News

Coherus BioSciences recently reported positive 24-week results from the second part of a three-part Phase 3 clinical trial comparing biosimilar CHS-1420, a therapy candidate for plaque psoriasis, to Humira (adalimumab). The results from ... Read more

January 17, 2017January 17, 2017

Possibly Pivotal Phase 3 Trial Shows Combo Lotion, IDP-118, Ably Treats Plaque Psoriasis

News

Treatment with IDP-118 (halobetasol propionate and tazarotene), a lotion developed by Valeant Pharmaceuticals, successfully improved the signs and symptoms of plaque psoriasis, according to the results of a second and confirmatory ... Read more